{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:59:37Z","timestamp":1776988777334,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.clgc.2012.09.006","type":"journal-article","created":{"date-parts":[[2012,10,8]],"date-time":"2012-10-08T21:00:53Z","timestamp":1349730053000},"page":"149-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Quality of Life in Patients With Metastatic Renal Cell Carcinoma: Assessment of Long-Term Survivors"],"prefix":"10.1016","volume":"11","author":[{"given":"Courtney","family":"Carmichael","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram E.","family":"Yuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clayton","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joann","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junmi","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty","family":"Ferrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumanta Kumar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2012.09.006_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib2","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2012.09.006_bib3","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib4","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.09.006_bib6","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib7","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.09.006_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.clgc.2012.09.006_bib9","article-title":"Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): five-year (yr) overall survival (OS) data from a phase II trial","volume":"29","author":"Motzer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejca.2011.05.017","article-title":"Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial","volume":"48","author":"Cella","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2012.09.006_bib11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.bjc.6605552","article-title":"Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis","volume":"102","author":"Cella","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2012.09.006_bib12","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.2007.13.5145","article-title":"Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial","volume":"26","author":"Cella","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1634\/theoncologist.2010-0299","article-title":"Patient-reported outcomes in a phase III study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy","volume":"16","author":"Beaumont","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2012.09.006_bib14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.coc.0000258732.80710.05","article-title":"Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer","volume":"30","author":"Bukowski","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib15","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.bjc.6605647","article-title":"Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha","volume":"102","author":"Yang","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2012.09.006_bib16","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2012.09.006_bib18","first-page":"191","article-title":"Development and validation of the functional assessment of cancer therapy-kidney symptom index (FKSI)","volume":"4","author":"Cella","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jpainsymman.2008.08.013","article-title":"A comparison of the renal cell carcinoma-symptom index (RCC-SI) and the functional assessment of cancer therapy-kidney symptom index (FKSI)","volume":"38","author":"Rao","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clgc.2012.09.006_bib20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/bjc.2011.589","article-title":"Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma","volume":"106","author":"Cella","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2012.09.006_bib21","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jgo.2012.01.005","article-title":"Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803)","volume":"3","author":"Cohen","year":"2012","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.radonc.2012.04.006","article-title":"Effects of a dietary intervention on acute gastrointestinal side effects and other aspects of health-related quality of life: a randomized controlled trial in prostate cancer patients undergoing radiotherapy","volume":"103","author":"Pettersson","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib24","first-page":"614","article-title":"Association between changes in quality of life scores and survival in non-small cell lung cancer patients","volume":"21","author":"Gupta","year":"2012","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.clgc.2012.09.006_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/JOP.0922004","article-title":"Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa","volume":"5","author":"Cella","year":"2009","journal-title":"J Oncol Pract"},{"issue":"suppl","key":"10.1016\/j.clgc.2012.09.006_bib26","article-title":"Hand-foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)","volume":"29","author":"Michaelson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.09.006_bib27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2012.09.006_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2011.37.2516","article-title":"Complete remission with tyrosine kinase inhibitors in renal cell carcinoma","volume":"30","author":"Albiges","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767312001814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767312001814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:22:22Z","timestamp":1761564142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767312001814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1558767312001814"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2012.09.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of Life in Patients With Metastatic Renal Cell Carcinoma: Assessment of Long-Term Survivors","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2012.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}